Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data

Dalin Rifat, Brendan Prideaux, Radojka M. Savic, Michael E. Urbanowski, Teresa L. Parsons, Brian Luna, Mark A. Marzinke, Alvaro A. Ordonez, Vincent P. DeMarco, Sanjay K. Jain, Veronique Dartois, William R. Bishai, Kelly E. Dooley

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In clinical trials of two rifamycin antibiotics (rifampin and rifapentine) for treating tuberculosis (TB), patients with cavitary lung lesions did not appear to derive benefit from rifapentine. Rifapentine was found not to outperform rifampin, despite a lower minimum inhibitory concentration against Mycobacterium tuberculosis in mouse models of TB. To understand these findings, we have developed a rabbit model of TB that reliably develops lung cavities with features similar to those of patients with pulmonary cavitary TB. After single or multiple doses of rifampin or rifapentine that produced human-equivalent plasma exposures, rabbits were sacrificed at different time points after dosing. We measured site-of-disease drug pharmacokinetics and tissue drug distribution. We used pharmacokinetic-pharmacodynamic (PK/PD) modeling to estimate drug penetration into different types of tubercular lesions. Both drugs penetrated rabbit lung cellular lesions, as well as the fibrotic cavity wall of cavitary lesions (penetration coefficients ?1 compared to plasma). For the necrotic liquefied material inside cavitary lesions known as caseum (which contains high numbers of bacteria), the penetration coefficient was 1.0 for rifampin but only 0.25 for rifapentine. When estimates of site-of-disease drug PK were substituted into clinical PK/PD models, the relationship between site-of-action exposure and sputum culture conversion was significant (P < 10 ?7 ). We propose that poor penetration of rifapentine into lung cavitary lesions explains, in part, why rifapentine doses required to improve treatment outcomes in two phase 2 clinical trials were four times higher in TB patients with large cavities compared to TB patients without cavitary lung disease.

Original languageEnglish (US)
Article numbereaai7786
JournalScience Translational Medicine
Volume10
Issue number435
DOIs
StatePublished - Apr 4 2018
Externally publishedYes

Fingerprint

rifapentine
Rifampin
Tuberculosis
Pharmacokinetics
Clinical Trials
Rabbits
Lung
Pharmaceutical Preparations
Microbial Sensitivity Tests
Tissue Distribution
Sputum
Pulmonary Tuberculosis
Mycobacterium tuberculosis
Lung Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. / Rifat, Dalin; Prideaux, Brendan; Savic, Radojka M.; Urbanowski, Michael E.; Parsons, Teresa L.; Luna, Brian; Marzinke, Mark A.; Ordonez, Alvaro A.; DeMarco, Vincent P.; Jain, Sanjay K.; Dartois, Veronique; Bishai, William R.; Dooley, Kelly E.

In: Science Translational Medicine, Vol. 10, No. 435, eaai7786, 04.04.2018.

Research output: Contribution to journalArticle

Rifat, D, Prideaux, B, Savic, RM, Urbanowski, ME, Parsons, TL, Luna, B, Marzinke, MA, Ordonez, AA, DeMarco, VP, Jain, SK, Dartois, V, Bishai, WR & Dooley, KE 2018, 'Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data', Science Translational Medicine, vol. 10, no. 435, eaai7786. https://doi.org/10.1126/scitranslmed.aai7786
Rifat, Dalin ; Prideaux, Brendan ; Savic, Radojka M. ; Urbanowski, Michael E. ; Parsons, Teresa L. ; Luna, Brian ; Marzinke, Mark A. ; Ordonez, Alvaro A. ; DeMarco, Vincent P. ; Jain, Sanjay K. ; Dartois, Veronique ; Bishai, William R. ; Dooley, Kelly E. / Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. In: Science Translational Medicine. 2018 ; Vol. 10, No. 435.
@article{8634652eaf874d7abfba5dea544f2da9,
title = "Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data",
abstract = "In clinical trials of two rifamycin antibiotics (rifampin and rifapentine) for treating tuberculosis (TB), patients with cavitary lung lesions did not appear to derive benefit from rifapentine. Rifapentine was found not to outperform rifampin, despite a lower minimum inhibitory concentration against Mycobacterium tuberculosis in mouse models of TB. To understand these findings, we have developed a rabbit model of TB that reliably develops lung cavities with features similar to those of patients with pulmonary cavitary TB. After single or multiple doses of rifampin or rifapentine that produced human-equivalent plasma exposures, rabbits were sacrificed at different time points after dosing. We measured site-of-disease drug pharmacokinetics and tissue drug distribution. We used pharmacokinetic-pharmacodynamic (PK/PD) modeling to estimate drug penetration into different types of tubercular lesions. Both drugs penetrated rabbit lung cellular lesions, as well as the fibrotic cavity wall of cavitary lesions (penetration coefficients ?1 compared to plasma). For the necrotic liquefied material inside cavitary lesions known as caseum (which contains high numbers of bacteria), the penetration coefficient was 1.0 for rifampin but only 0.25 for rifapentine. When estimates of site-of-disease drug PK were substituted into clinical PK/PD models, the relationship between site-of-action exposure and sputum culture conversion was significant (P < 10 ?7 ). We propose that poor penetration of rifapentine into lung cavitary lesions explains, in part, why rifapentine doses required to improve treatment outcomes in two phase 2 clinical trials were four times higher in TB patients with large cavities compared to TB patients without cavitary lung disease.",
author = "Dalin Rifat and Brendan Prideaux and Savic, {Radojka M.} and Urbanowski, {Michael E.} and Parsons, {Teresa L.} and Brian Luna and Marzinke, {Mark A.} and Ordonez, {Alvaro A.} and DeMarco, {Vincent P.} and Jain, {Sanjay K.} and Veronique Dartois and Bishai, {William R.} and Dooley, {Kelly E.}",
year = "2018",
month = "4",
day = "4",
doi = "10.1126/scitranslmed.aai7786",
language = "English (US)",
volume = "10",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "435",

}

TY - JOUR

T1 - Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data

AU - Rifat, Dalin

AU - Prideaux, Brendan

AU - Savic, Radojka M.

AU - Urbanowski, Michael E.

AU - Parsons, Teresa L.

AU - Luna, Brian

AU - Marzinke, Mark A.

AU - Ordonez, Alvaro A.

AU - DeMarco, Vincent P.

AU - Jain, Sanjay K.

AU - Dartois, Veronique

AU - Bishai, William R.

AU - Dooley, Kelly E.

PY - 2018/4/4

Y1 - 2018/4/4

N2 - In clinical trials of two rifamycin antibiotics (rifampin and rifapentine) for treating tuberculosis (TB), patients with cavitary lung lesions did not appear to derive benefit from rifapentine. Rifapentine was found not to outperform rifampin, despite a lower minimum inhibitory concentration against Mycobacterium tuberculosis in mouse models of TB. To understand these findings, we have developed a rabbit model of TB that reliably develops lung cavities with features similar to those of patients with pulmonary cavitary TB. After single or multiple doses of rifampin or rifapentine that produced human-equivalent plasma exposures, rabbits were sacrificed at different time points after dosing. We measured site-of-disease drug pharmacokinetics and tissue drug distribution. We used pharmacokinetic-pharmacodynamic (PK/PD) modeling to estimate drug penetration into different types of tubercular lesions. Both drugs penetrated rabbit lung cellular lesions, as well as the fibrotic cavity wall of cavitary lesions (penetration coefficients ?1 compared to plasma). For the necrotic liquefied material inside cavitary lesions known as caseum (which contains high numbers of bacteria), the penetration coefficient was 1.0 for rifampin but only 0.25 for rifapentine. When estimates of site-of-disease drug PK were substituted into clinical PK/PD models, the relationship between site-of-action exposure and sputum culture conversion was significant (P < 10 ?7 ). We propose that poor penetration of rifapentine into lung cavitary lesions explains, in part, why rifapentine doses required to improve treatment outcomes in two phase 2 clinical trials were four times higher in TB patients with large cavities compared to TB patients without cavitary lung disease.

AB - In clinical trials of two rifamycin antibiotics (rifampin and rifapentine) for treating tuberculosis (TB), patients with cavitary lung lesions did not appear to derive benefit from rifapentine. Rifapentine was found not to outperform rifampin, despite a lower minimum inhibitory concentration against Mycobacterium tuberculosis in mouse models of TB. To understand these findings, we have developed a rabbit model of TB that reliably develops lung cavities with features similar to those of patients with pulmonary cavitary TB. After single or multiple doses of rifampin or rifapentine that produced human-equivalent plasma exposures, rabbits were sacrificed at different time points after dosing. We measured site-of-disease drug pharmacokinetics and tissue drug distribution. We used pharmacokinetic-pharmacodynamic (PK/PD) modeling to estimate drug penetration into different types of tubercular lesions. Both drugs penetrated rabbit lung cellular lesions, as well as the fibrotic cavity wall of cavitary lesions (penetration coefficients ?1 compared to plasma). For the necrotic liquefied material inside cavitary lesions known as caseum (which contains high numbers of bacteria), the penetration coefficient was 1.0 for rifampin but only 0.25 for rifapentine. When estimates of site-of-disease drug PK were substituted into clinical PK/PD models, the relationship between site-of-action exposure and sputum culture conversion was significant (P < 10 ?7 ). We propose that poor penetration of rifapentine into lung cavitary lesions explains, in part, why rifapentine doses required to improve treatment outcomes in two phase 2 clinical trials were four times higher in TB patients with large cavities compared to TB patients without cavitary lung disease.

UR - http://www.scopus.com/inward/record.url?scp=85045112808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045112808&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aai7786

DO - 10.1126/scitranslmed.aai7786

M3 - Article

VL - 10

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 435

M1 - eaai7786

ER -